Rockwell Medical, Inc. (RMTI)

US — Healthcare Sector
Peers: LFCR  KMDA  ITCI  AGRX  EGRX  RGC  PROC  CPIX  IXHL  AQST  EVOK  ADMP  GHSI  ACRX  SXTC  BFRI  HUGE  ACOR  LSDI  COLL  PAHC  ANIP  SSIC 

Automate Your Wheel Strategy on RMTI

With Tiblio's Option Bot, you can configure your own wheel strategy including RMTI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RMTI
  • Rev/Share 2.8653
  • Book/Share 0.9242
  • PB 1.0515
  • Debt/Equity 0.3405
  • CurrentRatio 2.9481
  • ROIC 0.0134

 

  • MktCap 33210973.0
  • FreeCF/Share 0.0652
  • PFCF 14.9397
  • PE -125.5523
  • Debt/Assets 0.1989
  • DivYield 0
  • ROE -0.009

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Rockwell Medical, Inc. (RMTI) Q1 2025 Earnings Call Transcript
RMTI
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral

Rockwell Medical, Inc. (NASDAQ:RMTI ) Q1 2025 Earnings Conference Call May 12, 2025 8:00 AM ET Company Participants Heather Hunter - SVP, Chief Corporate Affairs Officer Mark Strobeck - President & CEO Jesse Neri - CFO Conference Call Participants Ram Selvaraju - H.C. Wainwright Jeremy Pearlman - Maxim Group Operator Good morning, and welcome to Rockwell Medical's First Quarter 2025 Results Conference Call and Webcast.

Read More
image for news Rockwell Medical, Inc. (RMTI) Q1 2025 Earnings Call Transcript
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
RMTI
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative

Rockwell Medical (RMTI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.02 per share a year ago.

Read More
image for news Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
Rockwell Medical Announces First Quarter 2025 Results
RMTI
Published: May 12, 2025 by: Business Wire
Sentiment: Neutral

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces financial and operational results for the three months ended March 31, 2025.

Read More
image for news Rockwell Medical Announces First Quarter 2025 Results
Rockwell Medical to Release Fourth Quarter and Full-Year 2024 Results on Thursday, March 20, 2025
RMTI
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the fourth quarter and full-year ended December 31, 2024 on Thursday, March 20, 2025.

Read More
image for news Rockwell Medical to Release Fourth Quarter and Full-Year 2024 Results on Thursday, March 20, 2025

About Rockwell Medical, Inc. (RMTI)

  • IPO Date 1998-01-27
  • Website https://www.rockwellmed.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Dr. Mark Strobeck Ph.D.
  • Employees 244
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.